Danaher Co. (NYSE:DHR) Shares Purchased by Grimes & Company Inc.

Grimes & Company Inc. increased its position in shares of Danaher Co. (NYSE:DHR) by 0.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,390 shares of the conglomerate’s stock after purchasing an additional 43 shares during the period. Grimes & Company Inc.’s holdings in Danaher were worth $1,696,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of DHR. Cyndeo Wealth Partners LLC grew its stake in shares of Danaher by 1.8% in the 4th quarter. Cyndeo Wealth Partners LLC now owns 8,579 shares of the conglomerate’s stock valued at $1,969,000 after buying an additional 154 shares during the period. Geneos Wealth Management Inc. grew its position in Danaher by 2.4% in the fourth quarter. Geneos Wealth Management Inc. now owns 16,713 shares of the conglomerate’s stock worth $3,837,000 after acquiring an additional 399 shares during the period. Eclectic Associates Inc. ADV increased its stake in Danaher by 8.7% during the fourth quarter. Eclectic Associates Inc. ADV now owns 964 shares of the conglomerate’s stock worth $221,000 after acquiring an additional 77 shares during the last quarter. CX Institutional raised its position in Danaher by 2.1% in the fourth quarter. CX Institutional now owns 2,970 shares of the conglomerate’s stock valued at $682,000 after purchasing an additional 62 shares during the period. Finally, Manitou Investment Management Ltd. lifted its stake in shares of Danaher by 0.5% in the 4th quarter. Manitou Investment Management Ltd. now owns 92,685 shares of the conglomerate’s stock valued at $21,276,000 after purchasing an additional 481 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on DHR shares. Raymond James cut their price objective on Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research report on Tuesday, January 21st. Robert W. Baird reduced their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. Scotiabank started coverage on Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Finally, Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a research report on Thursday, October 31st. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Danaher has an average rating of “Moderate Buy” and an average price target of $285.55.

Danaher Trading Up 0.1 %

NYSE DHR opened at $245.95 on Friday. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70. The firm has a 50 day moving average of $235.33 and a two-hundred day moving average of $253.45. The stock has a market capitalization of $177.65 billion, a PE ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.